Overview
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Eligibility
Inclusion Criteria:
- Histologically or cytologically-documented solid tumors.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Demonstrate adequate organ function.
Exclusion Criteria:
- Prior history of or active malignant disease other than that being treated in this study.
- Known brain metastases or cranial epidural disease.
- A known hypersensitivity to the components of the study therapy or its' analogs.